Clinical trials
Bone and Soft Tissue Tumors clinical trials
Below are recruiting bone and soft tissue tumors clinical trials, each written for real people, not researchers. We’re tracking 75 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07514819Recruiting
Adaptive Proton Therapy Planning for Children With Cancer
This study tests a new way to plan proton radiation therapy (a precise type of cancer treatment) for children with solid tumors or Hodgkin's lymphoma. The goal is to improve how doctors adapt treatment during therapy to better target tumors while protecting healthy tissue.
Memphis, TennesseeAges Any age - NCT05146440RecruitingPhase 1/Phase 2
Test drug PM14 alone and with radiation for soft-tissue sarcoma
This early-phase study tests PM14 (a new cancer treatment) to see if it can shrink tumors in soft-tissue sarcoma. Some people also receive radiation, aiming to improve tumor control while keeping side effects manageable.
Zaragoza, AragonAges 18–75 - NCT06987370Recruiting
Radiation study for bone metastases with soft tissue mass
This trial tests a new way of giving radiation (SFRT and SCART) to bone metastases that have a soft tissue mass. It may be an option if you have limited spread and your organs are working well.
Jinan, ShandongAges 18–75 - NCT06239272RecruitingPhase 1/Phase 2
Personalized treatment for NRSTS in children and young adults
This trial tests a personalized treatment plan for children and young adults with a type of soft tissue sarcoma (NRSTS). It uses a combination of surgery, targeted radiation, and two drugs (pazopanib and selinexor) to fight cancer while reducing side effects. The study is looking for people who have not been treated before for this sarcoma.
Atlanta, GeorgiaAges Up to 30 years - NCT07727434Recruiting
Stress and Anxiety in People Having Biopsy for Bone or Soft Tissue Cancer
This study looks at how stress and anxiety levels change in people who are about to have a biopsy for a possible bone or soft tissue tumor. The goal is to better understand the emotional impact of waiting for results and starting treatment.
IstanbulAges 18 years+ - NCT04040205RecruitingPhase 2
Abemaciclib for sarcoma with specific cell-growth gene changes
This trial tests abemaciclib (a cancer medicine) in adults with advanced, unresectable bone or soft-tissue sarcoma that has certain gene changes in the “CDK pathway.” It aims to shrink tumors or slow growth in people whose tumors match the study’s biomarker and lab requirements.
Jacksonville, FloridaAges 18 years+ - NCT04181970Recruiting
Study of sarcoma care quality across Europe and Latin America
This observational study looks at information from people with sarcoma to understand how care is delivered across different centers. It does not test a new treatment, but may help improve future care and planning.
Buenos AiresAges 18–120 - NCT04394052Recruiting
Imaging tests for suspected bone or soft-tissue tumors
This trial studies new imaging methods to better identify and stage (find how far it has spread) suspected bone or soft-tissue tumors. It may help your care team choose the most accurate next steps based on your scans.
Nancy, LorraineAges 18 years+ - NCT04757337RecruitingPhase 3
Oral chemotherapy comparison for older advanced soft-tissue cancer
This trial compares two chemotherapy medicines—oral cyclophosphamide versus doxorubicin—in people age 65 and older with advanced soft-tissue sarcoma that can’t be cured with surgery or radiation. It aims to see which treatment works better and is more tolerable for this age group.
ToulouseAges 65 years+ - NCT04901702RecruitingPhase 1/Phase 2
Onivyde plus talazoparib or temozolomide for resistant solid tumors
This trial tests whether adding Onivyde to either talazoparib or temozolomide can shrink or control hard-to-treat (refractory or recurring) cancers in children and young adults. It aims to find safer dosing first, then look at how well the treatment works—especially for Ewing sarcoma.
Palo Alto, CaliforniaAges 1–30 - NCT05111964Recruiting
Ultrasound treatment for soft tissue sarcoma tumors
This trial tests a non-surgical ultrasound treatment (HIFU) that targets the tumor from the outside of the body. It may help by shrinking or controlling certain types of soft tissue sarcoma or desmoid tumors when they are hard to remove surgically or when surgery/chemo/radiation is not a good option.
Oxford, OxfordshireAges 18 years+ - NCT05468970Recruiting
Study of bone and soft tissue tumors and treatment outcomes
This study looks at people with bone or soft tissue tumors to understand their features, treatments used, and survival outcomes. It may help doctors learn which care approaches work best for different tumor subtypes.
Zhengzhou, HenanAges 6–99 - NCT06171282RecruitingEarly Phase 1
Virus therapy for advanced bone and soft tissue tumors
This trial tests an investigational virus therapy (R130) injected directly into tumors for people with advanced bone or soft tissue cancer who have exhausted standard treatments or choose not to pursue them.
ShanghaiAges 16–75 - NCT06171750RecruitingPhase 1
Study of ANK-101 for advanced solid tumors
This trial tests a new drug, ANK-101, injected directly into tumors to help fight advanced solid tumors that have spread or can't be treated with standard therapies. It may be an option if you have a tumor that can be reached for injection.
Bethesda, MarylandAges 18 years+ - NCT06474676RecruitingPhase 1
Modified immune cell therapy for advanced sarcoma
This trial tests a new treatment using your own immune cells (TILs) that have been modified to attack sarcoma tumors. It is for people with advanced soft tissue or bone sarcoma who have already tried at least one other therapy.
Houston, TexasAges 12 years+ - NCT06571734RecruitingPhase 2
XL092 for advanced sarcoma types
This trial tests an experimental drug called XL092 (zanzalintinib) for people with advanced leiomyosarcoma, bone sarcoma, or translocation-associated soft tissue sarcoma that has spread or cannot be removed by surgery. The drug is a type of targeted therapy that may stop cancer growth.
Chicago, IllinoisAges 18 years+ - NCT06599957Recruiting
Light-based drug delivery for sarcoma treatment
This trial tests a new light-based drug delivery system to treat sarcomas. It looks at how well this platform works during surgery or biopsy for patients with soft tissue or bone sarcomas.
Bologna, Emilia-RomagnaAges 2–85 - NCT06637007RecruitingPhase 2
Chidamide plus AK112 for advanced sarcoma after first treatment
This trial tests two new drugs (chidamide and AK112) together for people with advanced bone or soft tissue sarcoma that has not responded to standard first-line treatment. The goal is to see if this combination can shrink tumors or slow their growth.
Taiyuan, ShanxiAges 18–75 - NCT06674811Recruiting
Childhood cancer surgery recovery study
This study looks at how children and young adults recover after surgery for solid tumors. It also includes their caregivers to understand how resilience affects recovery.
Rochester, MinnesotaAges 3–25 - NCT06774729Recruiting
Predicting tumor spread using MRI in sarcoma or bone cancer
This trial uses MRI scans to create a model that may predict if a musculoskeletal tumor is spreading. It aims to help doctors decide on the best surgical treatment.
BolognaAges 18 years+ - NCT06935864Recruiting
Study of KLF4 and KLF7 in bone tumors
This study looks at two proteins, KLF4 and KLF7, in bone tumor samples. It aims to understand their role in osteosarcoma and Ewing sarcoma, which may help develop better treatments.
CairoAges 1 month–39 years - NCT06939855RecruitingPhase 2
QL1706 for advanced bone and soft tissue sarcoma
This trial tests an experimental drug called QL1706 for people with advanced sarcoma (a type of cancer that starts in bones or soft tissues like muscle or fat) that cannot be removed by surgery or has spread. The goal is to see if QL1706 can help shrink or control the cancer.
Guangzhou, GuangdongAges 18–75 - NCT07052383RecruitingPhase 1
DIT309 for advanced bone and soft tissue sarcomas
This trial tests a new cell therapy called DIT309 for people with advanced bone or soft tissue sarcoma that hasn't responded to standard treatments. It aims to see if this therapy is safe and effective.
Shanghai, Shanghai MunicipalityAges 8 years+ - NCT07066982RecruitingPhase 1/Phase 2
CAR T cells targeting CD146 and HER2 for advanced sarcomas
This trial tests a new type of immunotherapy where your own immune cells are modified to find and attack sarcoma cells that carry markers called CD146 or HER2. It is for people with advanced sarcoma who have already tried standard treatments.
Beijing, Beijing MunicipalityAges 21–90
Hear when a new Bone and Soft Tissue Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for bone and soft tissue tumors?
- Yes. Clin2 currently lists 75 recruiting bone and soft tissue tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a bone and soft tissue tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a bone and soft tissue tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.